SMAD4 and neoplasm: Both tumors possessed <i>TP53</i> Q192X mutation, whereas <i>SMAD4</i> S517T was found only in SCC, suggesting that both tumor components originated from a founder clone with a stop-gain mutation in <i>TP53</i>.